An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma

Trial Profile

An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs GDC 0349 (Primary)
  • Indications Non-Hodgkin's lymphoma; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jan 2013 Planned End Date changed from 1 Feb 2014 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 09 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top